8-K/A filing — Intellia Therapeutics, Inc. (NTLA)
Filed: 2026-11-13 AccNo: 0001193125-26-460948 Size: 29 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Intellia Therapeutics has completed patient enrollment for its Phase 3 MAGNITUDE-2 clinical trial of nexiguran ziclumeran (nex-z).
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0001193125-26-460948 Size: 29 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Intellia Therapeutics announced new clinical and patient-reported data for its CRISPR-based therapy, lonvoguran ziclumeran (lonvo-z), demonstrating significant reductions in hereditary angioedema attack rates.
Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.
J.P. Morgan analyst Brian Cheng maintained a 'Sell' rating on Intellia Therapeutics while raising the price target from $8 to $9.
Intellia Therapeutics announced that it will participate in the upcoming Jefferies Global Healthcare Conference in London.
Intellia Therapeutics awarded equity-based inducement grants to three new employees as a material inducement to employment.